Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting

Abstract

Purpose: Lung cancer (LC) and its treatment impose a significant burden on patients' life. However, patient-centered outcomes are rarely collected during patient follow-up. Filling this gap, the International Consortium for Health Outcomes Measurement (ICHOM) developed a standard set of variables for newly diagnosed LC patients. In order to facilitate the use of this standard set, the project aims to adapt it to the Spanish setting. Methods: The variables (instrument and periodicity) to be included in Spanish standard set were selected through consensus during 4 nominal groups (13 oncologists, 14 hospital pharmacists, 4 hospital managers and 3 LC patients), under the supervision of a Scientific Committee (1 oncologist, 3 hospital pharmacists, 2 LC patients advocates). Results: The variables agreed upon included: (1) case-mix: demographic [age, sex, education and social-family support], clinical [weight loss, smoking status, comorbidities (Charlson index), pulmonary function (FEV-1)], tumor [histology, clinical, and pathological stage (TNM), EGFR, ALK, ROS-1, PD-L1] and treatment factors [intent and completion] and (2) outcomes: degree of health [performance status (ECOG) and quality-of-life (EQ-5D, LCSS)], survival [overall survival and cause of death], quality of death [place of death, end-of-life care and palliative care, death aligned with living will], treatment complications, and others [date of diagnosis and treatment initiation, productivity loss (sick leave)]. Conclusion: The adaptation of ICHOM standard set to the Spanish setting pave the way to standardize the collection of variables in LC.

Quality measurement for cardiovascular diseases and cancer in hospital value-based healthcare: a systematic review of the literature

“…Survival measures (e.g., overall and disease-free survival) were commonly reported as measures of value by patients, clinicians, and other stakeholders involved in the development of the outcome sets in the included studies ( n = 21) [ 39 , 40 , 42 , 44 , 49 , 51 , 55 – 60 , 63 – 65 , 68 – 71 , 74 , 75 ]. In addition, some studies reported that measuring all-cause mortality is superior to disease or cause-specific mortality, which is less meaningful to patients and harder to capture due to the non-availability or limited reliability of data related to the cause of death [ 42 , 56 , 57 ].…”

“…In some studies ( n = 3), the Patient Health Questionnaire was used as a complementary tool for the generic tools to measure anxiety and depression aspects [ 43 , 56 , 57 ]. The European Quality of Life (EuroQoL) tool was mainly used in studies of cancer [ 39 , 60 , 65 , 72 , 74 , 75 ]. Longitudinal data and measurements of PROMs were used in almost all studies.…”

“…Longitudinal data and measurements of PROMs were used in almost all studies. In contrast to measuring QoL, 4 studies of cancer disease recommended measuring the quality of death by clinicians for patients at the end of life [ 58 , 63 , 71 , 74 ]. PREMs were reported by one study in cardiovascular disease [ 49 ] and another study in cancer [ 61 ].…”

“…This theme consists of outcomes that patients (across medical conditions) would value in terms of timeliness of recovery and fast return to normal activities. Five studies reported quality measures in this theme [ 39 , 65 , 68 , 71 , 74 ]. PROMs were used for outcomes like access to care and medications [ 39 , 68 ] and time to recover and return to work [ 65 ].…”

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide

“…The value of pharmacist-led team care in pharmacotherapies has been demonstrated in numerous studies ( Yamamoto et al, 2018 ; Escudero-Vilaplana et al, 2020 ; Satsuma et al, 2020 ; Ji et al, 2021 ; Jia et al, 2021 ; Marzal-Alfaro et al, 2021 ; Miura et al, 2021 ; Xu et al, 2021 ). The results of this study revealed that pharmacist-urologist collaborative management can also improve care for patients with CRPC receiving enzalutamide in an ambulatory care setting.…”